Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, 2-Period, 2-Sequence Crossover Phase I Study With a 1 Month run-in Period to Examine the Effect of Cladribine Tablets on the Pharmacokinetics of a Monophasic Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel (Microgynon) in Pre-Menopausal Women With Relapsing Multiple Sclerosis (RMS)

Trial Profile

A Randomized, Double-blind, 2-Period, 2-Sequence Crossover Phase I Study With a 1 Month run-in Period to Examine the Effect of Cladribine Tablets on the Pharmacokinetics of a Monophasic Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel (Microgynon) in Pre-Menopausal Women With Relapsing Multiple Sclerosis (RMS)

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Dec 2018

At a glance

  • Drugs Cladribine (Primary) ; Ethinylestradiol/levonorgestrel
  • Indications Multiple sclerosis
  • Focus Pharmacokinetics
  • Sponsors Merck KGaA
  • Most Recent Events

    • 27 Nov 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top